Professor, Department of Pharmacy,
BITS Pilani, Pilani Campus
S.No | Title of the project | Funding agency | Principal Investigator /Co-investigator | Type of project |
Amount (Lakhs)
|
1 |
Identification and characterization of novel long non-coding RNAs in AKI-CKD transition using CRISPR/Cas9-based epigenome editing: revealing the potential of long non-coding RNAs as a biomarker and therapeutic strategy | ICMR | Principal Investigator | EMR | 41.85 |
2 | Interdisciplinary life science programme for advanced research and education in epigenetics and genome editing | DBT | Co-investigator | BUILDER | 975 |
3 | Novel pharmacological interventions against chronic kidney disease using clinically approved Inodilators, ET-1A antagonists, and Bisphosphonates: drug repurposing approach | SERB | Principal Investigator | EMEQ | 36.12 |
4 | Design, synthesis, and evaluation of novel dual inhibitors of angiotensin-II type 1 receptor and neprilysin for the treatment of diabetic cardiomyopathy | SERB | Co-investigator | CRG | 33.02 |
5 | Pharmacological intervention using α-Klotho with AT1 receptor blocker and sodium-glucose co-transporter 2 (SGLT-2) inhibitor against diabetic kidney disease | SERB | Principal Investigator | CRG | 38.62 |
6 | Design, synthesis, and evaluation of novel dual inhibitors of dipeptidyl peptidase 4 (DPPIV) and neprilysin for the treatment of diabetes | ICMR | Co-investigator | IIRP | 41.12 |
S.No | Title of the project | Funding agency | Principal Investigator /Co-investigator | Type of project | Amount (Lakhs) |
1 | Klotho regulation as a novel therapeutic strategy against acute kidney injury-diabetes comorbidity: Impact of epigenetic driven and epigenetic independent reactivation of endogenous Klotho expression | SERB | Principal Investigator | EMEQ | 50.33 |
2 |
To study the role of hyperglycemia on the progression of acute kidney injury
|
SERB | Principal Investigator | Early Carrier Research Award | 47.18 |
3 | Understanding hyperglycemia induced alterations in non-coding RNA expression pattern and post translational histone protein modifications contributing to drug resistance and progression of pancreatic cancer | DST-SERB | Co-investigator | EMR | 40.32 |
4 |
Peptide decorated pH sensitive nanoconjugate hybrid micelles for codelivery of temozolamide and an autophagy inducer, rapamycin for treatment of glioblastoma multiforme
|
DBT | Co-investigator | Nanobiotechnology | 41.94 |
5 |
Alternate day fasting resembles recurrent insulin-induced hypoglycemia model in rat
|
SERB | Mentor | NPDF | 19.20 |
6 | Role of histone ubiquitination & angiotensin converting enzyme 2 in the development of renal fibrosis under type I diabetic condition | CSIR, Govt of India | Principal Investigator | EMR |
14.86
|
7 | Effect of esculetin on the development of type II diabetic nephropathy | BITS | Principal Investigator | Research Initiation Grant | 2.00 |
8 | Effect of esculetin on angiotensin II in rat thoracic aorta under hyperglycaemic and hyperinsulinaemic conditions | UGC, Govt of India | Principal Investigator | Major Research Proposal | 13.43 |
9 | Understanding the epigenetic regulation in modulating inflammatory response mediated by NF-kB through AT1 or AT2 receptor in type II diabetic nephropathy | DST-SERB | Principal Investigator | Fast Track for Young Scientist | 22.21 |
10 | Esculetin a therapeutic intervention targeted at cardio-renal syndrome in type 2 diabetes | DST-SERB | Principal Investigator | Empowerment and Equity Opportunities for Excellence in Science | 39.66 |
This website uses cookies or similar technologies, to enhance your browsing experience.